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Background
Chronic anterior uveitis in JIA can be severe and common
immunosuppressive therapies may not be sufficient to
control uveitis. Concerning biological drugs, Enbrel is
usually ineffective, Infliximab is partially effective and is
frequently associated with side effects requiring drug sus-
pension, while Adalimumab, a TNF competitor, can be
successful.
Methods
We report on a girl aged 17 years, affected since one year
by a severe form of poliarticular JIA. She received immu-
nosuppressive therapy (Methotrexate, Azathioprine, etc.),
associated with oral steroids, with no articular benefit.
Results
When Enbrel plus Methotrexate was started she got into
remission. After one year of this therapy, she presented
uveitis in both eyes, so oral steroids were started again.
She obtained only partial ocular improvement, even
when she received Infliximab associated with Methotrex-
ate. Meantime she underwent cataract surgery with visus
reduction. After one year, Infliximab was suspended
because of an adverse reaction (dyspnea and rash) and
Adalimumab (0.7 mg/kg subcutaneous/14 days) associ-
ated with Methotrexate was started, with no side effects.
Fourteen months later there are no flare for uveitis and/or
arthritis. Following SUN criteria [1] we demonstrated ocu-
lar clinical improvement, not withstanding the presence
of signs of cataract and glaucoma.
Conclusion
During the last ten years, biological drugs have been really
useful to improve JIA outcome. In 2006 Biester S et al [2]
showed Adalimumab efficacy in controlling arthritis and
uveitis, with acceptable side effects, but further research is
needed.
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